Evidence map›Paper›PMID 39658078›Full record

ArticleClinical and experimental immunology2025

Experimental induction of anti-muscarinic type-3-receptor extracellular loop antibodies by immunization with 4-hydroxy-2-nonenal modified Ro60 and unmodified Ro60.

Biji T Kurien, Devavrat Dave, Martha Tsaliki, Syed M S Quadri, Valerie M Lewis, Robert Hal Scofield

Abstract read
In one paragraph

Article in Clinical and experimental immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Biji T KurienArthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, OK, USA.ORCID 0000-0002-7877-6859
Devavrat DaveArthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, OK, USA.
Martha TsalikiArthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, OK, USA.
Syed M S QuadriArthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, OK, USA.
Valerie M LewisArthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, OK, USA.
Robert Hal ScofieldArthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, OK, USA.

Funding

Tracking and Evaluation CoreU54GM104938 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI JUDITH A JAMES · 2013 to 2026
$68.2M
Sjogren's Syndrome Pathogenic AutoantibodiesR01DE028001 · NIDCR · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI SCOFIELD, ROBERT HAL · 2019 to 2023
$1.7M
Sjogren's model with anti-Ro/La and Salivary Pathology and DysfunctionR01DE017561 · NIDCR · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI SCOFIELD, ROBERT HAL · 2006 to 2010
$1.5M
NIDCR NIH HHS R01 DE017561NIDCR NIH HHS R01 DE028001NIGMS NIH HHS U54 GM104938NIH HHS GM104938
6 · The paper itself

Abstract

objectiveSjögren's Disease (SjD) subjects have decreased lacrimal/salivary gland function. Studies have proposed that autoantibodies targeting G-protein-coupled muscarinic acetylcholine-type-3-receptor (M3R) are potential clinical markers for SjD. We hypothesized that rabbits/mice immunized with 4-hydroxy-2-nonenal (HNE)-modified/unmodified Ro60 will develop an autoimmunity, specifically a SjD phenotype, thus expressing increased levels of anti-M3R antibodies.

methodsWe immunized two rabbits each with 10 mM HNE-modified Ro60/unmodified Ro60 antigen or Ro274-290/Ro413-428/Ro500-517 Ro60 peptides. Two rabbits each were immunized with either M3R second extracellular loop (ECL2) or M3R ECL3 peptide. Finally, five groups of BALB/c mice were immunized as follows-Group-I immunized with Ro60, Groups-II-IV immunized with Ro60 modified with 0.4 mM (low), 2 mM (medium), and 10 mM (high) HNE, respectively and Group-V-Freund's adjuvant. Serum antibodies to M3R ECL2/ECL3/Ro60/La or Sm were detected by ELISA. Functional assays were also performed.

resultsImmunization with HNE-modified Ro60/unmodified Ro60 antigen or Ro274/Ro 413/Ro500 peptides induced a rapid intermolecular epitope spreading to M3R ECL2/ECL3, especially to M3R ECL3 in HNE-Ro immunized rabbits. These animals did not bind to scrambled M3R peptides. Ro60-immunized rabbit IgG inhibited M3R activity in a functional assay. Rabbits immunized with ECL2/ECL3 developed high reactivity to Ro60 but not against Sm/RNP. We found a differential antibody-induction against M3R ECL2 with Group-3 mice developing significant reactivity.

conclusionOur data show induction of increasing anti-M3R antibodies in rabbits immunized with Ro60/HNE-Ro60 or Ro60 peptides and differential induction of these antibodies in mice immunized with Ro60 modified with increasing HNE. These findings suggest that M3R ECL2/ECL3 are involved in SjD autoimmunity progression.

Indexed as

AldehydesAutoantibodiesAutoantigensReceptor, Muscarinic M3RibonucleoproteinsRNA, Small CytoplasmicSjogren's SyndromeAnimalsAutoimmunityFemaleHumansImmunizationMiceMice, Inbred BALB CRabbitsSS-A Antigen4-hydroxy-2-nonenalAldehydesAutoantibodiesAutoantigensReceptor, Muscarinic M3RibonucleoproteinsRNA, Small CytoplasmicSS-A Antigenmuscarinic acetyl choline receptorRo60 (SSA) autoantigenSjögren’s disease

Identifiers

PMID39658078
PMCPMC11748001

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.